Houston, TX -- (SBWIRE) -- 12/11/2012 -- BG Medicine, Inc. (NASDAQ:BGMD) is currently trading at $3.01, 126.32% higher. BG Medicine, Inc., is a United States-based company, which provides drug research and development services. The Company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. Its products include avandia, and enbrel, remicade and molecular diagnostics for cardiovascular diseases, such as congestive heart failure, coronary stenosis, and vulnerable plaque, cancers, and central nervous system (CNS).